What is Larglustat?

Larglustat is an oral substrate reduction therapy (SRT) approved for the treatment of Gaucher's disease type 1 in adult patients. As a glucosylceramide synthase inhibitor, Larglustat works by reducing the production of glucosylceramide, the lipid that accumulates in Gaucher's disease due to deficient enzyme activity.

Gaucher's disease is the most common lysosomal storage disorder, affecting the body's ability to break down certain fatty substances. This leads to accumulation of these substances in various organs, particularly the spleen, liver, and bone marrow, causing a range of serious health complications.

Understanding Gaucher's Disease

What is Gaucher's Disease?

Gaucher's disease is an inherited metabolic disorder caused by a deficiency in the enzyme glucocerebrosidase (also called acid beta-glucosidase or GBA). This enzyme is responsible for breaking down glucosylceramide, a fatty substance. When this enzyme is deficient or absent, glucosylceramide accumulates in cells throughout the body, particularly in macrophages, which become engorged "Gaucher cells."

Types of Gaucher's Disease:

• Type 1 (Non-neuronopathic) — Most common form, affecting approximately 90% of patients. Does not involve the central nervous system. Symptoms can range from mild to severe and may include enlarged spleen and liver, bone disease, anemia, and thrombocytopenia.
• Type 2 (Acute neuronopathic) — Rare, severe form that begins in infancy and involves rapid neurological deterioration. Life expectancy is typically less than 2 years.
• Type 3 (Chronic neuronopathic) — Progressive form with neurological involvement that begins in childhood or adolescence. Slower progression than Type 2.

Prevalence and Genetics:

• Overall incidence: approximately 1 in 40,000–60,000 live births
• Higher prevalence in Ashkenazi Jewish population (approximately 1 in 850)
• Autosomal recessive inheritance pattern — both parents must carry the gene mutation
• Over 300 different mutations identified in the GBA gene

Common Symptoms and Complications:

• Hepatosplenomegaly (enlarged liver and spleen)
• Anemia and thrombocytopenia (low platelet count)
• Bone disease including bone pain, osteoporosis, avascular necrosis, and bone crises
• Fatigue and weakness
• Easy bruising and bleeding
• Delayed growth and puberty in children

How Larglustat Works — Substrate Reduction Therapy

Mechanism of Action: Glucosylceramide Synthase Inhibition

Unlike enzyme replacement therapy (ERT), which provides the missing enzyme, substrate reduction therapy takes a different approach by reducing the production of the substance that accumulates in Gaucher's disease.

How Larglustat Works:

• Larglustat inhibits the enzyme glucosylceramide synthase, which is responsible for the first step in the production of glucosylceramide
• By blocking this enzyme, Larglustat reduces the amount of glucosylceramide substrate being produced
• This reduction in substrate production helps balance the body's limited ability to break down glucosylceramide (due to the deficient glucocerebrosidase enzyme)
• The result is decreased accumulation of glucosylceramide in macrophages and improved disease manifestations

Substrate Reduction vs. Enzyme Replacement:

• Oral administration (Larglustat) vs. intravenous infusion (ERT)
• Different mechanism of action — reduces production vs. enhances breakdown
• Can be used as an alternative for patients who cannot receive or prefer not to receive infusions
• Important: Patient's CYP2D6 metabolizer status affects eligibility (see dosing section)

Clinical Efficacy and Studies

Larglustat (Eliglustat) is an FDA-approved oral substrate reduction therapy (SRT) for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The drug was originally approved as Cerdelga (eliglustat) and is available in India as Larglustat through Laurus Rare Diseases.

Pivotal Clinical Trial Results:

• Primary Endpoints — Organ Volume Reduction: Clinical studies demonstrated significant reductions in spleen volume and liver volume in treatment-naive patients with Gaucher disease type 1, meeting pre-specified primary endpoints.
• Haematological Improvements: Eliglustat has been shown to be effective in improving haematological parameters including haemoglobin levels and platelet counts, with significant improvements typically observed within 9 to 12 months of starting treatment.
• Bone-Related Outcomes: Studies showed stabilisation or improvement in bone mineral density and bone marrow infiltration. Larglustat helps reduce the skeletal complications associated with Gaucher disease, including bone pain and bone crises.
• Biomarker Data: Tracking of disease biomarkers including glucosylsphingosine and chitotriosidase demonstrated consistent reduction with Larglustat therapy, confirming ongoing therapeutic response and effective substrate reduction.
• Quality of Life: Patient-reported outcomes showed improvements in quality of life, fatigue, and physical functioning with long-term Larglustat treatment, reflecting the benefits of a convenient oral therapy over intravenous enzyme replacement.
• Published Studies: Clinical evidence is available via the FDA prescribing information and peer-reviewed publications on eliglustat in Gaucher disease type 1. For the full prescribing information, refer to: https://dailymed.nlm.nih.gov

Long-term Efficacy Data:

Long-term extension studies of eliglustat have demonstrated sustained maintenance of therapeutic effect over several years. Patients showed continued stability or improvement in spleen and liver volumes, haemoglobin levels, and platelet counts. The full extent of therapeutic effects continues to develop over several years of treatment, with disease stability confirmed through ongoing biomarker monitoring. Larglustat is not a cure but has been shown effective in improving haematological and visceral parameters and maintaining long-term disease stability.

Patient Eligibility and CYP2D6 Testing

Who Can Take Larglustat?

Larglustat is indicated for adult patients with Gaucher's disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-approved test.

What is CYP2D6 Testing?

CYP2D6 is a liver enzyme that metabolizes Larglustat. Genetic variations affect how quickly or slowly a person metabolizes the drug. Before starting Larglustat, patients must undergo genetic testing to determine their CYP2D6 metabolizer status.

CYP2D6 Metabolizer Categories:

• Extensive Metabolizers (EMs) — Normal enzyme activity
• Intermediate Metabolizers (IMs) — Reduced enzyme activity
• Poor Metabolizers (PMs) — Little to no enzyme activity
• Ultra-rapid Metabolizers (UMs) — Not eligible for Larglustat treatment

How to Get CYP2D6 Testing:

Before starting Larglustat, patients must be selected using an FDA-cleared test for determining CYP2D6 genotype. This pharmacogenetic test is typically performed via a blood or saliva sample and is ordered by the treating physician or metabolic specialist. Patients should consult their healthcare provider or a clinical genetics laboratory for access to CYP2D6 genotyping. Ultra-rapid metabolizers (UMs) are not eligible for Larglustat and should be managed with alternative therapies such as enzyme replacement therapy (ERT). For support, contact Laurus Rare Diseases at 7337585050.

Dosing and Administration

Dosing Based on CYP2D6 Status

Patient selection must be done using an FDA-cleared CYP2D6 genotyping test prior to prescribing. Recommended doses based on metabolizer status are as follows:

• Extensive Metabolizers (EMs) and Intermediate Metabolizers (IMs): 84 mg orally twice daily
• Poor Metabolizers (PMs): 84 mg orally once daily

Available Dosage Forms:

• Eliglustat 84 mg hard capsules — available in boxes of 56 capsules (₹1,69,500 per box, as of November 2025). For purchase, call: 7337585050.

Administration Instructions:

• Take once or twice daily as prescribed based on CYP2D6 status
• Can be taken with or without food
• Swallow capsules whole; do not crush, dissolve, or open
• If a dose is missed, take the next dose at the regular scheduled time

Drug Interactions Affecting Dosing:

• Strong and moderate CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine)
• Strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine)
• Important note: CYP2D6 inhibitors can convert EMs to functional PMs, requiring dose adjustments. Strong CYP3A inducers can decrease eliglustat levels significantly, potentially reducing efficacy. Co-administration with strong CYP2D6 inhibitors plus strong or moderate CYP3A inhibitors is contraindicated in EMs. Patients switching from ERT (imiglucerase, velaglucerase alfa, or taliglucerase alfa) may start Larglustat 24 hours after the last ERT dose. For patients currently on ERT, Larglustat may be administered at the next scheduled time.

Safety Profile and Side Effects

Most Common Adverse Reactions:

• The most common adverse reactions (≥10%) reported in clinical trials are: fatigue, headache, nausea, diarrhoea, back pain, pain in extremities, and upper abdominal pain.
• Additional adverse reactions reported include: upper respiratory tract infection, arthralgia, dizziness, and oropharyngeal pain. Most adverse events are mild to moderate in intensity and do not require discontinuation of treatment.

Warnings and Precautions:

• Cardiac Arrhythmias: Larglustat is not recommended in patients with pre-existing cardiac disease, long QT syndrome, or those with concomitant use of Class IA and Class III antiarrhythmic medications. Eliglustat can cause dose-dependent increases in cardiac conduction intervals (PR, QTc, QRS).
• ECG Monitoring: Periodic ECGs are required to monitor for cardiac interval changes, particularly in patients with pre-existing heart conditions or those taking interacting medications that may affect cardiac conduction.
• Drug Interactions: CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, ketoconazole) can increase eliglustat blood levels and risk of cardiac events. Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) can reduce eliglustat levels and effectiveness. Avoid grapefruit and grapefruit juice, which act as strong CYP3A inhibitors and can raise eliglustat levels to dangerous concentrations, increasing risk of cardiac side effects.

Contraindications:

• CYP2D6 ultra-rapid metabolizers (UMs — Larglustat cannot achieve adequate therapeutic concentrations in this population).
• Co-administration with strong CYP2D6 inhibitors plus strong or moderate CYP3A inhibitors in EM patients, or with strong CYP3A inhibitors in PM patients, is contraindicated due to risk of significant eliglustat accumulation and cardiac adverse events.

Use in Specific Populations:

Pregnancy and Lactation: Larglustat is not recommended for use in pregnant or breastfeeding women due to lack of adequate data and potential risks to the infant. Women of childbearing potential should use effective contraception during treatment.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Larglustat is approved for adult patients only.

Geriatric Use: Clinical studies of eliglustat did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently. Caution should be exercised when prescribing to elderly patients, particularly regarding cardiac and renal function.

Hepatic and Renal Impairment: Larglustat is not recommended in patients with moderate or severe hepatic impairment. In patients with mild hepatic impairment or any degree of renal impairment, dose adjustments may be required based on CYP2D6 metabolizer status and the severity of impairment. Regular monitoring of liver and kidney function is recommended during treatment.

Monitoring and Follow-up

Recommended Monitoring Parameters:

• Complete blood count (CBC) — hemoglobin and platelet counts
• Spleen and liver volume (via imaging — MRI or CT)
• Bone assessments (DXA scans, MRI for bone marrow infiltration)
• Disease biomarkers (chitotriosidase, CCL18, glucosylsphingosine)
• ECG monitoring — required at baseline and periodically during treatment, especially in patients with pre-existing cardiac conditions, those taking CYP2D6 or CYP3A interacting medications, or whenever cardiac symptoms arise
• Clinical symptoms and quality of life assessments

Frequency of Monitoring:

Recommended monitoring schedule: At baseline, assess full blood count, organ volumes via MRI/CT, bone density (DXA), biomarkers (glucosylsphingosine, chitotriosidase), ECG, and liver/kidney function. Repeat blood counts and biomarkers at 3 and 6 months after initiation, then every 6 months. Organ volume imaging should be repeated at 12 months, then annually. Bone assessments are recommended every 1–2 years. Cardiac monitoring via ECG should be performed as clinically indicated, particularly in patients on interacting medications. Screen for new drug interactions at every visit.

Larglustat vs. Eliglustat and Other Treatments

Understanding the Treatment Landscape:

Gaucher's disease type 1 has several treatment options, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Understanding the differences can help patients and providers make informed decisions.

Substrate Reduction Therapies (SRT):

• Eliglustat (Cerdelga) — First-line SRT, similar mechanism to Larglustat
• Larglustat — Laurus Rare Diseases' brand of eliglustat (84 mg capsules), an oral SRT offering the same active ingredient and mechanism as Cerdelga. Larglustat provides a convenient, once- or twice-daily oral option for eligible adult patients with GD1, serving as an alternative for those who prefer oral therapy over IV infusions or who wish to transition from ERT. Its efficacy is equivalent to other eliglustat formulations.
• Miglustat — Older SRT, different mechanism (iminosugar)

Enzyme Replacement Therapies (ERT):

• Imiglucerase (Cerezyme)
• Velaglucerase alfa (VPRIV)
• Taliglucerase alfa (Elelyso)

Key Comparison Points:

• Route of administration: Oral (SRT) vs. IV infusion (ERT)
• Efficacy: Generally comparable for spleen/liver volume reduction and hematological improvements
• Patient preference: Convenience of oral therapy vs. established track record of ERT
• Eligibility: SRT requires CYP2D6 testing; ERT available for all patients
• Bone disease: Long-term bone outcomes being studied for both approaches

For Healthcare Professionals

Patient Selection and Treatment Initiation:

• Confirm Gaucher's disease type 1 diagnosis (enzyme testing, genetic testing)
• Order CYP2D6 genotyping before prescribing
• Assess baseline disease severity (organomegaly, cytopenias, bone involvement)
• Review medication list for CYP2D6 and CYP3A interactions
• Discuss treatment goals and expectations with patient

Switching from ERT to SRT:

For patients currently treated with imiglucerase, velaglucerase alfa, or taliglucerase alfa (ERT), Larglustat may be initiated 24 hours after the last ERT dose. Before switching, confirm the patient's CYP2D6 metabolizer status using an FDA-cleared genotyping test, review all current medications for CYP2D6 and CYP3A interactions, obtain a baseline ECG, and establish baseline organ volume and haematological measurements to allow meaningful comparison of treatment response. Patients switching from ERT should be counselled on the difference in route of administration, the importance of daily oral adherence, and the timeline for assessing response (typically 9–12 months).

Resources for Prescribers:

• Full Prescribing Information: Available at https://dailymed.nlm.nih.gov — search for eliglustat capsules for complete prescribing information, contraindications, and drug interaction guidance.
• Dosing Reference: Dosing is based on CYP2D6 metabolizer status: EMs and IMs receive 84 mg twice daily; PMs receive 84 mg once daily. Refer to full prescribing information for dose adjustment guidance with interacting medications.
• Medical Information Contact: Laurus Rare Diseases customer care: 7337585050 | www.laurusrarediseases.com/Larglustat.html
• CME and Educational Resources: Continuing medical education resources on Gaucher disease management are available through the National Gaucher Foundation (NGF) at www.gaucherdisease.org and the European Working Group on Gaucher Disease (EWGGD). Clinical guidelines and review articles are available via PubMed and rare disease specialist networks.

For Patients and Caregivers

Living with Gaucher's Disease:

• Understanding your diagnosis and treatment options
• What to expect when starting Larglustat
• How to track your symptoms and treatment response
• When to contact your healthcare provider

Taking Larglustat:

• Setting up a medication schedule and reminders
• Managing side effects
• Importance of regular monitoring appointments
• What to do if you miss a dose

Daily Life and Quality of Life:

• Managing fatigue and bone pain
• Exercise and physical activity recommendations
• Emotional and psychological support
• Work and school considerations

Patient Support and Resources

Financial Assistance Programs:

• Laurus Rare Diseases patient assistance: For information on affordability support, pricing, and availability of Larglustat (eliglustat 84 mg capsules), contact Laurus Rare Diseases directly at customer care number 7337585050 or visit www.laurusrarediseases.com/Larglustat.html
• Co-pay and affordability support: Patients are encouraged to speak with their treating physician or hospital pharmacist about available support schemes. Government-run rare disease programs and insurance schemes such as CGHS and state health missions in India may cover treatment costs for eligible patients.
• Insurance and reimbursement support: Patients can seek guidance on insurance navigation and reimbursement through their hospital's medical social work department or rare disease patient advocacy groups such as the Organisation for Rare Diseases India (ORDI) at www.ordi.in, which provides support for navigating insurance and financial assistance for rare disease treatments.
• CYP2D6 genetic testing: Patients require CYP2D6 genotyping before starting Larglustat. This test is ordered by the treating physician and performed at accredited clinical genetics or molecular pathology laboratories. Patients should ask their doctor about access to pharmacogenetic testing at their treating centre. Contact Laurus Rare Diseases at 7337585050 for guidance on accessing testing support.

Patient Advocacy and Support Organizations:

• National Gaucher Foundation (NGF)
• National Organization for Rare Disorders (NORD)
• Genetic and Rare Diseases Information Center (GARD)
• Global Genes

Educational Resources:

• Patient guide downloads: Detailed patient guides on Gaucher disease, substrate reduction therapy, and living with GD1 are available through the National Gaucher Foundation (NGF) at www.gaucherdisease.org and the Organisation for Rare Diseases India (ORDI) at www.ordi.in
• Video resources: Educational videos about Gaucher disease, how substrate reduction therapy works, and patient stories are available on the National Gaucher Foundation YouTube channel and via NORD's rare disease video library at www.rarediseases.org
• Webinars and patient education events: The National Gaucher Foundation (NGF) and Global Genes regularly host patient education webinars, support groups, and annual conferences. Visit www.gaucherdisease.org/events and www.globalgenes.org for upcoming events relevant to Gaucher disease patients and caregivers.
• FAQ documents: A comprehensive FAQ on Larglustat (eliglustat), Gaucher disease type 1, CYP2D6 testing, and treatment management is available on the Laurus Rare Diseases product page at www.laurusrarediseases.com/Larglustat.html

Frequently Asked Questions (FAQ)

References and Scientific Literature

• Pivotal clinical trial publications
• FDA approval documents and label
• Gaucher's disease epidemiology studies
• Glucosylceramide synthase mechanism research
• CYP2D6 pharmacogenetics literature
• Comparative effectiveness studies (SRT vs. ERT)